Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension to a Randomized, Double-blind, Sham-controlled, Adaptive-Design Pivotal Study of Sensory Stimulation in Subjects With Alzheimer's Disease (OLE Hope Study, CA-0015)

NCT06245031 is registered in ClinicalTrials.gov with Cognito Therapeutics, Inc. as lead sponsor.

NCT NCT06245031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06245031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension to a Randomized, Double-blind, Sham-controlled, Adaptive-Design Pivotal Study of Sensory Stimulation in Subjects With Alzheimer's Disease (OLE Hope Study, CA-0015)
Lead sponsor
Cognito Therapeutics, Inc.
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
February 29, 2024
Completion date
March 31, 2027
Enrollment
402 (estimated)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

ad, alzheimer disease, cognitive impairment, dementia alzheimers, dementia moderate, dementia of alzheimer type, dementia, mild, mild cognitive impairment